Last reviewed · How we verify
Insulin Lispro Mix50
Insulin Lispro Mix50 is a Insulin analog, rapid-acting (premixed formulation) Small molecule drug developed by Eli Lilly and Company. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: LY275585-50.
Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Insulin Lispro Mix50 is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro Mix50 |
|---|---|
| Also known as | LY275585-50 |
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin analog, rapid-acting (premixed formulation) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin Lispro is a rapid-acting human insulin analog created by reversing the order of the last two amino acids (lysine and proline) of human insulin, allowing faster absorption and onset of action. Mix50 is a 50/50 premixed formulation combining 50% rapid-acting insulin lispro with 50% insulin lispro protamine suspension (intermediate-acting), designed to provide both mealtime and basal insulin coverage in a single injection. This combination mimics physiologic insulin secretion patterns in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes (PHASE4)
- Comparison of Insulin Mix25 Versus Mix50 (PHASE4)
- A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics (PHASE3)
- Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects (PHASE1)
- A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients (PHASE4)
- Efficacy of Insulin Lispro Mix 50/50 Therapy (NA)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Lispro Mix50 CI brief — competitive landscape report
- Insulin Lispro Mix50 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Insulin Lispro Mix50
What is Insulin Lispro Mix50?
How does Insulin Lispro Mix50 work?
What is Insulin Lispro Mix50 used for?
Who makes Insulin Lispro Mix50?
Is Insulin Lispro Mix50 also known as anything else?
What drug class is Insulin Lispro Mix50 in?
What development phase is Insulin Lispro Mix50 in?
What are the side effects of Insulin Lispro Mix50?
What does Insulin Lispro Mix50 target?
Related
- Drug class: All Insulin analog, rapid-acting (premixed formulation) drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Eli Lilly and Company — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: LY275585-50
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing